The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study

Abraham Campos-Romero, Karen S. Anderson, Adhemar Longatto-Filho, Marco A. Luna-Ruiz Esparza, David J. Morán-Portela, Javier A. Castro-Menéndez, José L. Moreno-Camacho, Diana Y. Calva-Espinosa, Manuel A. Acosta-Alfaro, Freddy A. Meynard-Mejía, Marlene Muñoz-Gaitán, Jonathan Alcántar-Fernández

Research output: Contribution to journalArticle

Abstract

In Mexico, HPV vaccines available immunize against genotypes 16/18 and 16/18/6/11; however, there is limited surveillance about carcinogenic subtypes in different states of the country that allow evaluating the effectiveness of vaccination and cervical cancer screening programs. Here, we report the regional and age-specific prevalence of 14 hr-HPV genotypes as well as their prevalence in abnormal cytology (from ASCUS to cervical cancer) among Mexican women which were undergoing from cervical cancer screening in the Salud Digna clinics in 20 states of the country. This study includes women with social security from the majority of public health institutions (IMSS, ISSSTE, SEMAR, and PEMEX), and women without social security. For cervical cancer screening, we used the SurePath liquid-based cytology and the BD Onclarity HPV Assay. From December 1, 2016, to August 2, 2018, the hr-HPV prevalence among 60,135 women was 24.78%, the most prevalent types were HPV 16 (4.13%), HPV 31 (4.12%) and HPV 51 (3.39%), while HPV 18 (1.70%) was less prevalent among infected women. Interestingly, the genotypes not covered by current vaccines in Mexico were commonly found in precancerous lesions, evidencing their carcinogenic potential, so it is necessary to increase their surveillance and inclusion in cervical cancer screening triage.

Original languageEnglish (US)
Article number10094
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019
Externally publishedYes

Fingerprint

Mexico
Early Detection of Cancer
Uterine Cervical Neoplasms
Cross-Sectional Studies
Genotype
Social Security
Cell Biology
Human papillomavirus 31
Papillomavirus Vaccines
Human papillomavirus 18
Human papillomavirus 16
Triage
Vaccination
Vaccines
Public Health

ASJC Scopus subject areas

  • General

Cite this

Campos-Romero, A., Anderson, K. S., Longatto-Filho, A., Luna-Ruiz Esparza, M. A., Morán-Portela, D. J., Castro-Menéndez, J. A., ... Alcántar-Fernández, J. (2019). The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study. Scientific reports, 9(1), [10094]. https://doi.org/10.1038/s41598-019-46543-8

The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico : a cross-sectional study. / Campos-Romero, Abraham; Anderson, Karen S.; Longatto-Filho, Adhemar; Luna-Ruiz Esparza, Marco A.; Morán-Portela, David J.; Castro-Menéndez, Javier A.; Moreno-Camacho, José L.; Calva-Espinosa, Diana Y.; Acosta-Alfaro, Manuel A.; Meynard-Mejía, Freddy A.; Muñoz-Gaitán, Marlene; Alcántar-Fernández, Jonathan.

In: Scientific reports, Vol. 9, No. 1, 10094, 01.12.2019.

Research output: Contribution to journalArticle

Campos-Romero, A, Anderson, KS, Longatto-Filho, A, Luna-Ruiz Esparza, MA, Morán-Portela, DJ, Castro-Menéndez, JA, Moreno-Camacho, JL, Calva-Espinosa, DY, Acosta-Alfaro, MA, Meynard-Mejía, FA, Muñoz-Gaitán, M & Alcántar-Fernández, J 2019, 'The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study', Scientific reports, vol. 9, no. 1, 10094. https://doi.org/10.1038/s41598-019-46543-8
Campos-Romero, Abraham ; Anderson, Karen S. ; Longatto-Filho, Adhemar ; Luna-Ruiz Esparza, Marco A. ; Morán-Portela, David J. ; Castro-Menéndez, Javier A. ; Moreno-Camacho, José L. ; Calva-Espinosa, Diana Y. ; Acosta-Alfaro, Manuel A. ; Meynard-Mejía, Freddy A. ; Muñoz-Gaitán, Marlene ; Alcántar-Fernández, Jonathan. / The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico : a cross-sectional study. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{ff1e1744b08841d697b9344ddf2f4ffb,
title = "The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study",
abstract = "In Mexico, HPV vaccines available immunize against genotypes 16/18 and 16/18/6/11; however, there is limited surveillance about carcinogenic subtypes in different states of the country that allow evaluating the effectiveness of vaccination and cervical cancer screening programs. Here, we report the regional and age-specific prevalence of 14 hr-HPV genotypes as well as their prevalence in abnormal cytology (from ASCUS to cervical cancer) among Mexican women which were undergoing from cervical cancer screening in the Salud Digna clinics in 20 states of the country. This study includes women with social security from the majority of public health institutions (IMSS, ISSSTE, SEMAR, and PEMEX), and women without social security. For cervical cancer screening, we used the SurePath liquid-based cytology and the BD Onclarity HPV Assay. From December 1, 2016, to August 2, 2018, the hr-HPV prevalence among 60,135 women was 24.78{\%}, the most prevalent types were HPV 16 (4.13{\%}), HPV 31 (4.12{\%}) and HPV 51 (3.39{\%}), while HPV 18 (1.70{\%}) was less prevalent among infected women. Interestingly, the genotypes not covered by current vaccines in Mexico were commonly found in precancerous lesions, evidencing their carcinogenic potential, so it is necessary to increase their surveillance and inclusion in cervical cancer screening triage.",
author = "Abraham Campos-Romero and Anderson, {Karen S.} and Adhemar Longatto-Filho and {Luna-Ruiz Esparza}, {Marco A.} and Mor{\'a}n-Portela, {David J.} and Castro-Men{\'e}ndez, {Javier A.} and Moreno-Camacho, {Jos{\'e} L.} and Calva-Espinosa, {Diana Y.} and Acosta-Alfaro, {Manuel A.} and Meynard-Mej{\'i}a, {Freddy A.} and Marlene Mu{\~n}oz-Gait{\'a}n and Jonathan Alc{\'a}ntar-Fern{\'a}ndez",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-46543-8",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico

T2 - a cross-sectional study

AU - Campos-Romero, Abraham

AU - Anderson, Karen S.

AU - Longatto-Filho, Adhemar

AU - Luna-Ruiz Esparza, Marco A.

AU - Morán-Portela, David J.

AU - Castro-Menéndez, Javier A.

AU - Moreno-Camacho, José L.

AU - Calva-Espinosa, Diana Y.

AU - Acosta-Alfaro, Manuel A.

AU - Meynard-Mejía, Freddy A.

AU - Muñoz-Gaitán, Marlene

AU - Alcántar-Fernández, Jonathan

PY - 2019/12/1

Y1 - 2019/12/1

N2 - In Mexico, HPV vaccines available immunize against genotypes 16/18 and 16/18/6/11; however, there is limited surveillance about carcinogenic subtypes in different states of the country that allow evaluating the effectiveness of vaccination and cervical cancer screening programs. Here, we report the regional and age-specific prevalence of 14 hr-HPV genotypes as well as their prevalence in abnormal cytology (from ASCUS to cervical cancer) among Mexican women which were undergoing from cervical cancer screening in the Salud Digna clinics in 20 states of the country. This study includes women with social security from the majority of public health institutions (IMSS, ISSSTE, SEMAR, and PEMEX), and women without social security. For cervical cancer screening, we used the SurePath liquid-based cytology and the BD Onclarity HPV Assay. From December 1, 2016, to August 2, 2018, the hr-HPV prevalence among 60,135 women was 24.78%, the most prevalent types were HPV 16 (4.13%), HPV 31 (4.12%) and HPV 51 (3.39%), while HPV 18 (1.70%) was less prevalent among infected women. Interestingly, the genotypes not covered by current vaccines in Mexico were commonly found in precancerous lesions, evidencing their carcinogenic potential, so it is necessary to increase their surveillance and inclusion in cervical cancer screening triage.

AB - In Mexico, HPV vaccines available immunize against genotypes 16/18 and 16/18/6/11; however, there is limited surveillance about carcinogenic subtypes in different states of the country that allow evaluating the effectiveness of vaccination and cervical cancer screening programs. Here, we report the regional and age-specific prevalence of 14 hr-HPV genotypes as well as their prevalence in abnormal cytology (from ASCUS to cervical cancer) among Mexican women which were undergoing from cervical cancer screening in the Salud Digna clinics in 20 states of the country. This study includes women with social security from the majority of public health institutions (IMSS, ISSSTE, SEMAR, and PEMEX), and women without social security. For cervical cancer screening, we used the SurePath liquid-based cytology and the BD Onclarity HPV Assay. From December 1, 2016, to August 2, 2018, the hr-HPV prevalence among 60,135 women was 24.78%, the most prevalent types were HPV 16 (4.13%), HPV 31 (4.12%) and HPV 51 (3.39%), while HPV 18 (1.70%) was less prevalent among infected women. Interestingly, the genotypes not covered by current vaccines in Mexico were commonly found in precancerous lesions, evidencing their carcinogenic potential, so it is necessary to increase their surveillance and inclusion in cervical cancer screening triage.

UR - http://www.scopus.com/inward/record.url?scp=85068973555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068973555&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-46543-8

DO - 10.1038/s41598-019-46543-8

M3 - Article

C2 - 31300693

AN - SCOPUS:85068973555

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 10094

ER -